Duchenne Muscular Dystrophy (DMD) influences millions globally, necessitating a robust market for effective treatments. The existing DMD treatment landscape is characterized by an focus on symptom management and supportive care. However, recent developments in gene therapy and pharmaceuticals are opening the way for possible curative treatments. R